JP2015502387A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502387A5
JP2015502387A5 JP2014548061A JP2014548061A JP2015502387A5 JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5 JP 2014548061 A JP2014548061 A JP 2014548061A JP 2014548061 A JP2014548061 A JP 2014548061A JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5
Authority
JP
Japan
Prior art keywords
hal
formula
alkyl
independently
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548061A
Other languages
English (en)
Japanese (ja)
Other versions
JP6129203B2 (ja
JP2015502387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076595 external-priority patent/WO2013092979A1/en
Publication of JP2015502387A publication Critical patent/JP2015502387A/ja
Publication of JP2015502387A5 publication Critical patent/JP2015502387A5/ja
Application granted granted Critical
Publication of JP6129203B2 publication Critical patent/JP6129203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548061A 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤 Expired - Fee Related JP6129203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579076P 2011-12-22 2011-12-22
EP11195107 2011-12-22
EP11195107.5 2011-12-22
US61/579,076 2011-12-22
PCT/EP2012/076595 WO2013092979A1 (en) 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Publications (3)

Publication Number Publication Date
JP2015502387A JP2015502387A (ja) 2015-01-22
JP2015502387A5 true JP2015502387A5 (https=) 2016-02-18
JP6129203B2 JP6129203B2 (ja) 2017-05-17

Family

ID=48667763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548061A Expired - Fee Related JP6129203B2 (ja) 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤

Country Status (15)

Country Link
US (1) US9688702B2 (https=)
EP (1) EP2793900B1 (https=)
JP (1) JP6129203B2 (https=)
KR (1) KR20140114391A (https=)
CN (1) CN104321060B (https=)
AU (1) AU2012356890B2 (https=)
BR (1) BR112014015363A8 (https=)
CA (1) CA2860142C (https=)
EA (1) EA201400735A1 (https=)
ES (1) ES2699267T3 (https=)
HK (1) HK1206261A1 (https=)
IL (1) IL233200A (https=)
MX (1) MX352652B (https=)
SG (2) SG11201403254QA (https=)
WO (1) WO2013092979A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2015008627A (es) * 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3193904B1 (en) 2014-08-18 2025-10-01 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
RU2017115193A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
BR112017006420A2 (pt) 2014-10-01 2017-12-19 Merck Patent Gmbh derivados de ácido borônico
RU2017115191A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102764027B1 (ko) 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
PL3672977T3 (pl) 2017-08-24 2022-09-26 Merck Patent Gmbh Pochodne kwasu boronowego
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC PROTEASOME INHIBITORS
CN107556336A (zh) * 2017-10-16 2018-01-09 康化(上海)新药研发有限公司 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法
MA50906A (fr) 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome
ES2928787T3 (es) 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
CN108130370B (zh) * 2018-01-05 2020-11-17 武汉惠康达科技有限公司 Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202100727VA (en) 2018-07-26 2021-02-25 Merck Patent Gmbh Boronic acid derivatives
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
CN116940580A (zh) * 2021-03-05 2023-10-24 Agc株式会社 化合物、化合物的制造方法及表面处理剂的制造方法
WO2023006863A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
CN118119630A (zh) * 2021-10-14 2024-05-31 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
WO2025111328A1 (en) 2023-11-21 2025-05-30 VenatoRx Pharmaceuticals, Inc. Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7332343B2 (en) 2004-01-16 2008-02-19 Board Of Regents, The University Of Texas System Determining enantiomeric excess using indicator-displacement assays
HRP20212002T1 (hr) * 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
CA2668662A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2007357338B2 (en) * 2007-08-06 2014-03-20 Takeda Pharmaceutical Company Limited Proteasome inhibitors
WO2009051581A1 (en) * 2007-10-16 2009-04-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
CA2705393A1 (en) * 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US8513218B2 (en) * 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8507494B2 (en) 2010-04-30 2013-08-13 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived M1 receptor positive allosteric modulators

Similar Documents

Publication Publication Date Title
JP2015502387A5 (https=)
JP2022541467A (ja) オーロラキナーゼ阻害剤およびその使用
AU2020262221B2 (en) 4H-pyrrolo(3,2-c)pyridin-4-one compounds
JP2009524691A5 (https=)
JP2017511357A5 (https=)
JP2018537483A (ja) ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
EA023826B1 (ru) Дигидропиримидинизохинолиноны и содержащие их фармацевтические композиции для лечения воспалительных нарушений
JP2016534146A5 (https=)
JP2008503591A5 (https=)
JP2016500661A5 (https=)
BR112015023142B1 (pt) Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende
JP2011523945A5 (https=)
JP2013536259A5 (https=)
JP2016530338A5 (https=)
JP2015501327A5 (https=)
KR20210005668A (ko) Hpk1 억제제, 그의 제조 방법 및 응용
EP2001872A1 (en) Benzofuran compounds as ep1 receptor antagonists
JP2016532669A5 (https=)
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
JP2015535851A5 (https=)
JP2019532092A5 (https=)
JP2010518146A (ja) ベンゾフラン化合物
JP2009513718A5 (https=)
AU2009335159B2 (en) Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2015502371A5 (https=)